Zero deaths from tuberculosis: progress, reality, and hope
To commemorate World TB Day 2013, The Lancet Infectious Diseases is publishing a Series of articles on tuberculosis, a disease that has long plagued human beings and was declared a global emergency in 1993 by WHO. At that time, most Mycobacterium tuberculosis strains were susceptible to fi rst-line tuberculosis drugs, and global control of the disease seemed a realistic goal. However, tuberculosis persists as one of the main causes of death from infectious disease: in 2011, 8·7 million incident cases causing 1·4 million deaths were estimated. 1 Roughly 630 000 cases of multidrugresistant (MDR) tuberculosis occur worldwide, and extensively drug-resistant (XDR) tuberculosis is now reported in 84 countries.
1 Although the total global burden of tuberculosis is higher today than ever before, promising new diagnostic, drug, and vaccine pipelines provide hope for improved control of the disease.
In 2013, insuffi cient rapid, accurate point-of-care tuberculosis diagnostic tests, and the widespread unavailability of facilities to test for drug resistance, remain important impediments to global activities of tuberculosis control. In the fi rst article of this Series, Stephen Lawn and colleagues 2 review recent advances in the development of new tuberculosis diagnostics. Although the Xpert MTB/RIF assay was rapidly endorsed by WHO in 2010 and is deemed a landmark diagnostic method, Lawn and colleagues point out the drawbacks and challenges facing the rapid roll-out of the assay in areas endemic for tuberculosis and HIV. Whether the test will accelerate progress towards the Millennium Development Goal of tuberculosis control targets is uncertain because many implementation issues could limit the eff ect of the Xpert MTB/RIF assay. Therefore, the urgent need for rapid, accurate, aff ordable, pointof-care tuberculosis diagnostic tests that are easy to use and implement remains a priority.
Accelerated antimicrobial development has created a range of promising new drugs and drug regimens against drug-sensitive and drug-resistant tuberculosis, which are now under clinical evaluation. Recent approval by the US Food and Drug Administration of delamanid for use in adults with MDR tuberculosis heralds the fi rst new tuberculosis drug on the market since the introduction of rifampicin in the 1970s. Tuberculosis biomarkers are essential for accelerated development and assessment of these new drugs to capture the full eff ects of these interventions on clinical outcomes in many prospective, randomised clinical trials. In the second article of the Series, Robert Wallis and colleagues 3 look at the many M tuberculosis and human biomarkers. Despite recent scientifi c progress, discovery of accurate, clinically useful, prognostic biomarkers of tuberculosis remains elusive.
The increase in non-communicable diseases worldwide, and in particular in developing countries, now poses a competing factor on the unfi nished agenda of communicable diseases in developing countries. In the third article of the Series, Ben Marais and colleagues 4 warn that a broad holistic approach to health-care See Online/Series http://dx.doi.org/10.1016/ S1473-3099(13)70015-X, http://dx.doi.org/10.1016/ S1473-3099(13)70025-2, http://dx.doi.org/10.1016/ S1473-3099(13)70030-6, and http://dx.doi.org/10.1016/ S1473-3099(13)70042-2 Gustoimages/Science Photo Library delivery is needed. The investigators point out major overlaps between non-communicable diseases and communicable diseases and justify improved integration of tuberculosis and HIV care with services for noncommunicable diseases to enhance the effi ciency of public-health services. In the present global economic recession, resources targeted for specifi c diseases through vertical funding streams need to be integrated more broadly across health-care systems. In the fourth article in the Series, William Wells and colleagues 5 recommend the prioritisation of rapid drug-susceptibility testing through improved delineation of molecular mechanisms of resistance and by the association of genetic polymorphisms with drug resistance. The authors discuss tuberculosis regimens, diagnostics, and drugsusceptibility testing and prioritise which future drugs to test, how to test them, and the development of new well characterised collections of M tuberculosis strains for the study of new drug-susceptibility testing assays. In low-income settings, surveillance data and modelling will help to design appropriate drug-susceptibility testing algorithms, assist in regimen change nationally, and clinical decision making for individual patients.
In the fi fth article, Ibrahim Abubakar and colleagues 6 refer to the rising tide of MDR and XDR tuberculosis in eastern Europe, Asia, and Africa as a wake-up call for everybody, including governments of high-income countries. Most laboratories in countries with a high burden of tuberculosis are ill equipped to detect and diagnose the extent of drug resistance; therefore, most MDR tuberculosis and XDR tuberculosis cases are undocumented and unreported. As the history of tuberculosis in developed countries has shown, sustained investment in tuberculosis control and research programmes are needed to have a substantial and lasting eff ect. 
Progress and challenges in childhood tuberculosis
The plight of children with tuberculosis is widely recognised and is increasingly becoming a priority for national tuberculosis control programmes. In 2012, WHO attempted for the fi rst time to quantify the tuberculosis disease burden in children, estimating there to be 490 000 cases and 65 000 deaths in 2011. 1 Some limitations of this estimation were recognised within the WHO report 1 (table) , such as the assumption that the ratio of notifi ed to incident cases is the same for children and adults, even though under-reporting of child tuberculosis cases is very common. The estimated number of children with tuberculosis equates to less than 6% of all incident cases (8·7 million), whereas estimates from tuberculosis endemic areas suggest proportions of 10-15%.
2 Furthermore, tuberculosisrelated deaths in children infected with HIV were classifi ed as deaths due to HIV (not tuberculosis). Additionally, many children who die of common disorders such as severe pneumonia and malnutrition might have unrecognised tuberculosis. Unfortunately, child tuberculosis data reported by national tuberculosis control programmes are often incomplete and hampered by restricted diagnostic access in most tuberculosis endemic areas.
2 Children are frequently diagnosed in settings where the accuracy and quality of non-microbiological diagnoses is weak and 
